The aim of the present study was to evaluate retrospectively the influence of various auxological and laboratory parameters on final height in a group of GH-deficient children after replacement therapy and to compare their final height with that of a group of short children with normal GH secretion and hence not treated.
Introduction
More than 30 years experience with growth hormone (GH) treatment has produced various reports on the final height of the patients treated (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . However, insufficient numbers of patients, different therapy durations, and changes in the time of the dosage prescribed, due, in particular, to a greater availability of the hormone, have led to different results (10, 11) . In addition, the modifications recently made in the therapy schedule and administration route, as well as the uncertainties of the diagnostic criteria indicating the subjects to be treated (13) (14) (15) (16) (17) (18) (19) (20) (21) , will probably further change the final results of the treatment. It is certain, however, that the experience acquired to date has not enabled us to adopt an optimal therapeutic approach, either for the single patient or for the whole group, casting doubt on the auxological outcome of the patients treated.
This is a report of our experience on the final height of 83 patients affected by isolated GH deficiency, according to the commonly used criteria, who were treated with recombinant human GH (hGH) for periods ranging from 2 to 7 years at a dose of 15-20 U/m 2 per week with six to seven s.c. injections/week. The diagnostic uncertainties regarding GH deficiency led us to consider also the final height of a group of patients with clinical characteristics similar to those of the patients treated but with a normal GH secretion and therefore not treated.
Patients and methods

Patients
We examined 83 patients (51 males and 32 females) with isolated GH deficiency. All subjects were submitted to two pharmacological tests (arginine and L-dopa) and to sampling for nocturnal integrated GH secretion with a constant withdrawal pump. The criteria used to define GH deficiency were: GH peak <8 mg/l after two pharmacological tests and/or mean GH concentration <3.3 mg/l during the night (20) . The patients were treated with hGH for periods ranging from 24 to 84 months until they reached final height (growth velocity <0.5 cm/year in the last year). At diagnosis no subjects presented any disturbances apart from GH deficiency and they reached final height without other endocrinological problems. In particular, none of the children exhibited any signs of malnutrition, hypothyroidism, malabsorbtion, obesity or other obvious causes of growth retardation. All patients had a neonatal weight appropriate for gestational age. Sex chromatin, tested in the girls, was normal in all cases. All patients had normal magnetic resonance imaging of the sellar area. No patients had GH antibody titres which could have influenced the results of the tests performed. Besides idiopathic and isolated GH deficiency, the inclusion criterion for all patients was treatment with recombinant hGH, via s.c. injection 6 or 7 days a week in the evening, at a dose of 15 U/m 2 per week (the dose was adjusted every 6 months) and from 1994 at a dose of 20 U/m 2 week (only eleven subjects, seven prepubertal and four pubertal at the start of therapy, completed treatment with 20 U/m 2 week). At the start of therapy all patients but four had a stature inferior or equal to the 3rd centile with median height for chronological age (CA) standard deviation score (SDS) of ¹2.21 (interquartile range (IQR) from ¹2.63 to ¹1.73). Four subjects, two males (CA 12.7 and 13.2 years) and one female (CA 11.6 years) in Tanner pubertal stages 2-3 and one prepubertal female (CA 9.6 years) with heights ranging from the 3rd to the 10th centile were examined since, in the last 12 months, they had presented a growth velocity of less than 3 cm/year and a predicted height lower than target height. They had a delayed bone age (BA) (from ¹1.0 to ¹2.2 years).
Mean CA of the 83 subjects at diagnosis was 12.2 Ϯ 1.7 years (range from 8 to 15.7) while bone age was 10.7 years (range from 5 to 13.5) and was delayed in all cases (from ¹1.0 to ¹5.2 years). At the start of therapy 35 patients were prepubertal while 48 had already started puberty. Every 6 months all patients underwent auxological evaluation, blood test and left hand X-ray for BA determination. All subjects had a GH secretion re-evaluation at least once during puberty (Tanner pubertal stage 3). The results confirmed a pathological GH secretion in all cases.
The rather late age of our patients at diagnosis was partly due to the fact that younger children who started GH treatment at the reported dose have not yet reached final height, and possibly also because of a greater sensitivity towards growth problems in the parents of older children.
We also considered 51 subjects with clinical characteristics initially similar to those of the deficient subjects (42 males and 9 females; 29 prepubertal and 22 pubertal at diagnosis with mean CA 11.6 Ϯ 2.4 years). When examined in the same period, they presented a normal GH secretion and therefore were not treated. These subjects reached their final height in the same period as the 83 subjects treated. They were all subjects recalled without selection who came to our department to have their final height evaluated.
Methods
Arginine and L-dopa tests were performed as previously described (17) . For the sleep test, a constant withdrawal pump, as described by Kowarski et al. (22) , was used at a rate of approximately 2.5 ml/h. Collection tubes were changed hourly.
Target height was calculated as sex-corrected midparental height expressed in SDS units. Height was measured in the morning with a Harpenden stadiometer. BA was evaluated according to the method of Greulich & Pyle (23) , and pubertal stage according to the procedure of Marshall & Tanner (24, 25) . Height was expressed as SDS for CA and BA, and height velocity as SDS for BA, according to Tanner standards (26, 27) . In the subjects with BA >6 years, predicted height was calculated with the method of Bayley & Pinneau (28) at the beginning of treatment and at onset of puberty in the subjects initially prepubertal; these data were compared with the final height.
Hormone assay
Serum GH was measured by a commercial solid phase sandwich fluoroimmunoassay (Cyberfluor, Inc., Toronto, Ontario, Canada) using time-resolved fluorescence spectroscopy. The standards were calibrated against reference preparation WHO 80/205. The intra-and interassay coefficients of variations were 7.8% and 10.7% respectively, at the level of 1.2 mg/l, and 6.3% and 9.9% at the level of 12.5 mg/l. Cross-reactivity was less than 1% for prolactin and human placental lactogen. Sensitivity of the assay was 0.1 mg/l, as determined by the mean+2S.D. of the zero standard. All samples from each child were studied in the same assay.
Statistical analysis
For statistical analysis the computer program Statistical Package for Social Science (SPSS Inc., Chicago, IL, USA) was used on an IBM computer. Data distribution was analyzed with skewness and kurtosis coefficients. Normally distributed data are expressed as means Ϯ S.D. and non-normally distributed data as median and IQR; the IQR is the distance between the 25th and 75th percentile and encompasses the middle 50% of observations. For normally distributed data the statistical significance was assessed using Student's t-test and r Pearson correlation coefficient. For non-normally distributed data the MannWhitney test and r Pearson correlation coefficient computed on the ranks was used. Chi-square test was used to compare the proportions of subjects improving target height in the untreated and treated subjects. All results nominally significant at P<0.05 are indicated. Table 1 shows the essential clinical data (therapy duration, CA, BA, height for CA and BA at start of therapy, final and target height) of the 83 patients considered together and subdivided according to sex and pubertal stage at the start of therapy. It also shows the auxological characteristics of the 51 untreated subjects: height for CA SDS and target height were similar to those of the treated subjects. In the treated subjects final height SDS was higher than that of control subjects (P ¼ 0.01). Both treated subjects and control subjects showed a final height lower than target height. Figure 1 considers those patients displaying a final height above target height. They represent 39% of the treated subjects as a whole (35% for males and 44% for females). Thirty-four percent of the group of subjects who were prepubertal at the start of therapy presented a final height above target height compared with 42% in the group starting therapy after the onset of puberty. In the untreated subjects only ten (20%) reached a final height above target height, a value which was significantly lower than that found in the treated subjects (P ¼ 0.035). a not normally distributed data (median and IQR). *P ¼ 0:01, † not significant compared with untreated subjects. subjects with normal GH secretion. In the treated patients, final height was significantly higher than predicted height only in females (P ¼ 0.001). In the untreated subjects, predominantly in males, final height was significantly lower than predicted height at diagnosis (P ¼ 0.007 in the whole group; P ¼ 0.0001 in males). Table 3 shows the statistically significant correlations found between final height and some auxological data in the treated subjects. In females, there was only one correlation between target and final height (P ¼ 0.0001). In males, final height was correlated with Bayley-Pinneau prediction at diagnosis, height for CA at diagnosis, height for BA at diagnosis and target height. In the patients who started therapy before the onset of puberty, the same correlations were also found at the onset of puberty, together with a correlation with CA at the onset of puberty. In contrast, in the whole group of patients, both males and females, there were no correlations between final height and the following parameters: BA at start, at second and third year of therapy, growth velocity during first year of therapy, therapy duration, BA increment during first year of therapy and BA delay at start and first year of therapy. In the untreated subjects there was a positive correlation between final height and Bayley-Pinneau prediction at diagnosis (n ¼ 41; r ¼ 0.58; P ¼ 0.001), target height (r ¼ 0.44; P ¼ 0.001), and height for CA SDS (r ¼ 0.28; P ¼ 0.02). Table 4 shows the final heights (SDS and cm) and the target heights (SDS and cm) in three groups of patients subdivided according to the amount of GH secretion at diagnosis (GH peak <8 mg/l and/or mean GH concentration Յ3.3 mg/l, GH peak <8 mg/l and mean GH concentration Յ3.3 mg/l, GH peak <4 mg/l and mean GH concentration Յ2 mg/l) and in the controls. The value of final height SDS and the percentage of subjects exceeding target height increased progressively from the group as a whole to the subjects with the most severe deficiency. Table 5 reports the final and target height SDS values in the patients improving their height for BA in the first year, in the first 2 years and in the first 3 years of therapy. There was a progressive increase in the percentage of subjects exceeding target height.
Results
Auxological data
Final height and GH secretion
Final height and initial response to therapy
The six subjects who improved their height for BA after 3 years of therapy and with final height above target height, showed a final height SDS 1.24 Ϯ 0.62 higher than CA height SDS at the start of therapy. Table 6 shows the mean height gain for CA from the start of therapy to final height in patients who were either prepubertal or pubertal at the start. For the former the mean height gain obtained both before and after onset of puberty is also reported. There was no difference in height gain between the patients starting therapy before or during puberty. The height gain obtained during puberty by the patients starting treatment after its onset was greater, although not statistically significant, than that obtained during puberty by the patients starting treatment before it.
Final height and puberty
Discussion
GH treatment in subjects with GH deficiency improves final height (1, 2, 5, 6, 29). To be considered as normal, final height should be similar to or higher than target
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Figure 1
Percentage of subjects with final height above target height in the GH-deficient group (subdivided according to sex and pubertal stage at the start of therapy) and in the untreated shortstature subjects with normal GH secretion. *P ¼ 0.035 compared with untreated subjects (chi-squared test).
Table 2
Predicted height SDS (means Ϯ S.D.) at start of therapy (Bayley-Pinneau method in the patients with BA Ն 6 years) and final heights in both treated and untreated subjects. height if we take into account the secular trend. Some investigations on final height have reported conflicting results with values, however, lower on average than target height (1, 2, 5, 8) .
Bayley-Pinneau Final Height (SDS) (SDS) P
Our study, which examined patients with idiopathic and isolated GH deficiency treated with hGH at a dose of 15-20 U/m 2 per week by s.c. injections six to seven times/ week, showed a mean final height in SDS lower than mean target height (¹1.30 Ϯ 0.91 vs ¹0.92 Ϯ 0.82). This is probably due not only to the GH deficit and to the insufficiency of the diagnostic and therapeutic criteria, but also to the fact that our patients were mainly 'short' subjects with familial short stature ( Table 1 ) and these subjects may not behave like the general population. This is supported also by the results of the untreated subjects with normal GH secretion, who, failing to follow the secular trend, presented a final height even lower than target height (¹1.70 Ϯ 0.85 vs ¹1.01 Ϯ 0.78).
The final height of our patients was slightly worse than that reported by Brämswig et al. (30) and better than that of the patients studied by Burns et al. (9) . If we examine the various studies such differences may be accounted for by the initial severity of the height and endocrine defect and by age at the start of therapy, and also by the dose of hGH used, the type of disorder considered (idiopathic isolated deficiency provides less satisfactory results), the type of schedule (three or more injections per week) and the method of administration (i.m. vs s.c.). The best results seem to be those obtained recently. It is likely that the advantage obtained from the stricter patient inclusion criteria in past studies is nullified by the increased doses and the changes in the therapy schedules used by the more recently treated subjects. The difference in height in our study between males and females was minimal (¹1.28 and ¹1.35 SDS respectively) ( Table 1) as too was the percentage of subjects with final height above target height (35% and 44% respectively) (Fig. 1) . Female patients, conversely, differed from males as regards final height which correlated only with target height, while in males it also correlated with predicted height, and height for CA and BA both at the start of therapy and at the onset of puberty (Table 3) . It is interesting to note that height prediction values calculated by the Bayley-Pinneau method were different in the two sexes ( Table 2 ). In males, in fact, final height practically overlapped with predicted height while in females this latter greatly underestimated final height. It would appear that in male subjects the biological behaviour of growth (ratio between growth in stature and bone maturation) before and after treatment is more regular. Overall the percentage of our patients with final height greater than target height (39%) was higher than that obtained by Brämswig et al. (30) (26%), who also considered these data.
The effect of GH secretion present at the time of diagnosis on the final result of treatment is usually clear and is characterized by a better response in the patients with so-called 'total' deficiency vs those with 'partial' defect (1, 2). Lenko et al. (31) , moreover, found no difference between the responses of the two types of GH deficiencies. In our patients, subdivided into three groups (Table 4) , the subjects with progressively impaired secretion seemed to show a tendency towards a better therapeutic response; this tendency was also consistent with a progressively higher number of patients exceeding target height (39%, 44% and 62% respectively). It should be pointed out that since the target height of the group with the most severe EUROPEAN 
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Final height of GH-deficient patients 57 Table 3 Correlations between final height SDS and auxological data at the start of therapy and at the onset of puberty in the prepubertal subjects at start of therapy.
All patients
Prepubertal patients (puberty onset) Table 4 Final heights, target heights and number of subjects (%) with final height > target height in relation to GH secretion. deficiency was better than the other groups, it is difficult to establish with certainty the role in the final height of GH deficiency and of the genetic potential: target height, in fact, was highly correlated statistically with final height of treated (both sexes) and untreated subjects. A further parameter useful for evaluating treatment seems to be the height trend for BA in the first years of therapy. As shown in Table 5 , the patients improving their height in the first, first 2 and first 3 years of treatment progressively increased their final stature. In particular, of the nine patients with an increment in height for BA in the first 3 years of therapy, as many as six (67%) exceeded target height and attained a final height SDS of ¹0.67 with a mean improvement vs CA height SDS measured at the start of therapy of 1.24 Ϯ 0.62. These findings, as well as the uncertainties in diagnosing GH deficiency (16, 17, 21) , emphasize the importance of follow-up to evaluate yearly the height for BA in order to continue therapy only in those patients showing an improvement. A suspension of treatment and a deeper examination of the GH-insulinlike growth factor-I (IGF-I) axis (20, 21) are indicated for those whose stature SDS worsens. In this situation, the therapeutical approach should probably be changed in some respects (therapy discontinuation, change in the dose and so on).
It is well known that patients with multiple pituitary deficiency reach a higher final height than patients with isolated deficiency. This depends both on the choice of timing of puberty, obviously more delayed in patients with multiple deficiency, and on the usually more severe secretory defects of such patients. It has also been reported that final height in the treated GH-deficient patient is correlated with BA (9) and stature (12, 31) at the onset of puberty. In our study too, final height (Table 3) was correlated with height for CA, predicted height, CA and height for BA at onset of puberty. All this would suggest, on the one hand, postponing the onset of puberty, in particular when height is clearly unsatisfactory and, on the other, starting the treatment as soon as possible in order to reduce the deficiency in stature. It is not clear, however, whether manipulation of the onset of puberty obtained with the use of luteinizing hormone-releasing hormone analogues is able to improve final height (32) (33) (34) (35) and here again we are faced with diagnostic uncertainties (21) . Since about 85-90% of final height in the normal subject is obtained before puberty, it would seem that the chances of improving final height during puberty are minimal. This is not always true in those with GH secretory defects. In fact, in the group of patients who started treatment after the onset of puberty (Fig. 1) , the number of subjects exceeding target height seems to be tendentially higher than in the initially prepubertal patients. Furthermore, in the initially pubertal patients, mean final height (Table 1) and mean SDS height gain were similar (Table 6) to those of the patients who started the treatment before puberty; thus SDS gain during puberty alone was greater than that obtained in the same period by the patients treated earlier. All this would seem to demonstrate that catch-up growth is more marked in those patients treated later and that the diagnosis of GH deficiency obtained during puberty is more reliable (20) .
A comparison between the clinical characteristics of the short-stature subjects treated because of GH deficiency and the untreated non-deficient subjects shows that at the time of first examination the two groups of patients were almost the same. Theoretically, if GH response defines with sufficient certainty the efficiency of the GH-IGF-I axis and this, together with target height, significantly expresses the growth capacities of the examined subjects, GH-deficient shortstature subjects, if treated, should grow similarly to those untreated short subjects with normal secretion. The comparison between the final heights of the two groups (Table 1) showed in reality that the treated GHdeficient subjects, presenting a similar target height to that of control subjects, reached a statistically higher final height (P ¼ 0.01) and had a significantly higher percentage with final height greater than target height (P ¼ 0.035). This would seem to demonstrate that GH therapy in subjects who are deficient is moderately useful and that a certain number of subjects diagnosed as normal were very likely actually 'pseudonormal' subjects (20) who had an unsatisfactory growth rate.
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Final height of GH-deficient patients 59 This also seem to be confirmed by the height prediction in males (Table 2 ).
In conclusion, the gain in stature observed in our treated patients along with the number of patients with a final height above target height and the favourable comparison with the untreated short-stature subjects seems promising. However, the present study seems to show that further improvement of diagnostic criteria and treatment schedules, as well as stricter clinical and endocrinological control of each patient, are necessary.
